tradingkey.logo

Carmat Gets FDA Conditional Approval To Start Second EFS Study Cohort In The US

ReutersApr 14, 2025 4:21 PM

- Carmat SA ALCAR.PA:

  • RECRUITMENT FOR SECOND COHORT EXPECTED TO BEGIN IN H2 2025

  • CARMAT: RECRUITMENT OF SECOND COHORT EXPECTED TO BEGIN IN H2 2025

  • CARMAT RECEIVES FDA CONDITIONAL APPROVAL TO INITIATE THE SECOND COHORT OF THE EFS STUDY IN THE UNITED STATES

  • TO INITIATE IMPLANTS IN SECOND HALF OF 2025

  • EFS STUDY INVOLVES 10 PATIENTS, PRIMARY ENDPOINT IS 6-MONTH SURVIVAL

  • TO SEEK FDA APPROVAL FOR LATEST VERSION OF AESON

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI